Published in Arch Neurol on January 01, 2004
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Translational research in neurology and neuroscience 2010-2011. Arch Neurol (2010) 1.96
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
Translating biomedical research to the bedside: a national crisis and a call to action. JAMA (2003) 1.63
Performance of elderly Native Americans and Caucasians on the CERAD Neuropsychological Battery. Alzheimer Dis Assoc Disord (2005) 1.60
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn (2006) 1.53
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord (2006) 1.53
Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry (2003) 1.53
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord (2002) 1.48
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Genome-wide association studies in Alzheimer disease. Arch Neurol (2008) 1.38
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci (2007) 1.17
Communicating clinical trial results to research participants. Arch Neurol (2008) 1.16
Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord (2005) 1.13
Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A (2008) 1.12
The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord (2008) 1.12
We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? Neurology (2002) 1.10
FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. Eur Radiol (2005) 1.09
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol (2008) 1.07
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA (2009) 1.07
Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci (2005) 1.06
Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci (2006) 1.05
Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 1.05
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol (2011) 1.02
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine (2010) 1.00
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord (2010) 0.96
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol (2012) 0.94
Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J Geriatr Psychiatry Neurol (2003) 0.93
In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 0.93
Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord (2013) 0.90
Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord (2011) 0.90
Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol (2014) 0.89
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord (2009) 0.89
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord (2010) 0.89
Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol (2010) 0.88
Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord (2009) 0.88
Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord (2006) 0.85
Treat Alzheimer disease before it is symptomatic. Arch Neurol (2011) 0.85
Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord (2011) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci (2012) 0.83
Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol (2013) 0.83
Prion proteins: physiological functions and role in neurological disorders. J Neurol Sci (2007) 0.83
Dementia diagnosis, treatment, and research with American Indians. Alzheimers Dement (2006) 0.82
Comparison of Alzheimer's disease in Native Americans and Whites. Int Psychogeriatr (2003) 0.82
Preempting genetic discrimination and assaults on privacy: report of a symposium. Am J Med Genet A (2003) 0.81
TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem Biophys Res Commun (2012) 0.81
Experimental neurotherapeutics: leaps and bounds. Arch Neurol (2002) 0.80
Neuromics and neurological disease. Arch Neurol (2008) 0.79
A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord (2014) 0.79
Atherosclerosis risk factors in American Indians with Alzheimer disease: preliminary findings. Alzheimer Dis Assoc Disord (2008) 0.79
Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study. PLoS Curr (2011) 0.79
Brain MRI, apoliprotein E genotype, and plasma homocysteine in American Indian Alzheimer disease patients and Indian controls. Curr Alzheimer Res (2009) 0.78
Mitochondrial therapy for Parkinson disease. Arch Neurol (2002) 0.78
Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine. Pharmacogenet Genomics (2014) 0.77
Increased risk for heterozygotes in recessive Parkinson disease. Arch Neurol (2006) 0.77
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol (2006) 0.77
Progranulin and tau gene mutations both as cause for dementia: 17q21 finally defined. Arch Neurol (2007) 0.77
High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med (2005) 0.77
Metal chelation therapy for Alzheimer disease. Arch Neurol (2003) 0.76
Explaining the cause of the amyloid burden in Alzheimer disease. Arch Neurol (2002) 0.76
New presenilin 1 mutation with Alzheimer disease and Lewy bodies. Arch Neurol (2005) 0.76
Treating Alzheimer disease: Time matters. Arch Neurol (2006) 0.76
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord (2009) 0.76
Juvenile-onset huntington disease: a matter of perspective. Arch Neurol (2007) 0.76
West Nile virus encephalomyelitis in transplant recipients. Arch Neurol (2004) 0.75
Notice of incomplete referencing. Arch Neurol (2009) 0.75
Time and memory. Arch Neurol (2002) 0.75
Reply: Unusual DAT scan results. Mov Disord (2013) 0.75
The relationship of cardiovascular risk factors to Alzheimer disease in Choctaw Indians. Am J Geriatr Psychiatry (2011) 0.75
Positive potential of fetal nigral implants for Parkinson disease. Arch Neurol (2004) 0.75
Immunotherapy for Alzheimer disease: the promise and the problem. Arch Neurol (2005) 0.75
Pain 2003. Arch Neurol (2003) 0.75
Comment on "American Indians/Alaska natives and dementia". Alzheimer Dis Assoc Disord (2003) 0.75
Unreported financial disclosures. Arch Neurol (2008) 0.75
Exercised against dementia. Arch Neurol (2009) 0.75
Measuring the effects of therapy in Parkinson disease. JAMA (2004) 0.75
HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology (2013) 0.75
Genes for movement. Arch Neurol (2004) 0.75
Unreported financial disclosure. Arch Neurol (2009) 0.75
Genes for movement. Arch Neurol (2004) 0.75
The JAMA network journals: new names for the archives journals. Arch Intern Med (2012) 0.75
The JAMA Network journals: new names for the archives journals. Arch Facial Plast Surg (2012) 0.75